RecruitingGerm Cell Cancer Metastatic
Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.
Sponsor: Indiana University
You may qualify if…
- ✓ 1. ≥ 18 years old at the time of informed consent
- ✓ 2. Ability to provide written informed consent and HIPAA authorization
- ✓ 3. Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.
- ✓ Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.
- ✓ 4. Archival tissue for germ-cell tumor diagnosis available
You may not qualify if…
- ✕ 1. Concurrent disease or condition that would make the subject inappropriate for study participation
- ✕ 2. Any serious medical disorder that would interfere with the subject's safety
- ✕ 3. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent per treating physician coverage.
- ✕ 4. Patient is being tested for minimal residual disease with other experimental platforms
Where it's recruiting
Indiana
Indianapolis
Source: ClinicalTrials.gov · NCT07401316 · last updated 2026-06-15